KYV-102
Autoimmune Diseases
Key Facts
About Kyverna Therapeutics
Kyverna Therapeutics is a clinical-stage biotech company with a mission to liberate autoimmune patients through the curative potential of engineered cell therapies. Founded in 2018 and publicly listed in 2024, the company has rapidly advanced its clinical pipeline, having treated over 100 patients across multiple autoimmune indications. Its strategy centers on translating the proven success of CD19-targeting CAR T-cells from oncology to autoimmunity, aiming to achieve deep B-cell depletion, immune reset, and long-term, treatment-free remission.
View full company profileTherapeutic Areas
Other Autoimmune Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| HBM7020 | Harbour BioMed | Discovery |
| R2006 | Harbour BioMed | Discovery |
| R7027 | Harbour BioMed | Discovery |
| ImmCelz™ Platform | Creative Medical Technology Holdings | Preclinical |
| Gavocabtagene autoleucel | Astellas | Phase 1/2 |
| miR-124 Activator | Formation Bio | Phase 2 |
| Autologous Cell Therapy Collaboration | Lupagen | Preclinical |
| Autoimmune Diagnostics Leadership Initiative | Vibrant America Clinical Laboratory | Commercial |
| I&I Portfolio | Third Arc Bio | Pre-clinical |
| Undisclosed Platform Programs | Zag Bio | Preclinical |
| E-602 | Palleon Pharmaceuticals | IND-Enabling |
| DIASPOT Platform Expansion | DIAsource ImmunoAssays | Commercial & Development |